ACADIA Pharmaceuticals, Inc. (ACAD)
29.63
+0.13
(+0.44%)
USD |
NASDAQ |
Aug 24, 16:00
29.63
0.00 (0.00%)
After-Hours: 20:00
ACADIA Pharmaceuticals Enterprise Value : 4.195B for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 4.195B |
| August 20, 2026 | 4.116B |
| August 19, 2026 | 4.317B |
| August 18, 2026 | 4.312B |
| August 17, 2026 | 4.111B |
| August 14, 2026 | 3.978B |
| August 13, 2026 | 4.002B |
| August 12, 2026 | 4.187B |
| August 11, 2026 | 4.180B |
| August 10, 2026 | 4.176B |
| August 07, 2026 | 4.145B |
| August 06, 2026 | 4.015B |
| August 05, 2026 | 4.075B |
| August 04, 2026 | 3.791B |
| August 03, 2026 | 3.526B |
| July 31, 2026 | 3.570B |
| July 30, 2026 | 3.687B |
| July 29, 2026 | 3.651B |
| July 28, 2026 | 3.595B |
| July 27, 2026 | 3.488B |
| July 24, 2026 | 3.393B |
| July 23, 2026 | 3.391B |
| July 22, 2026 | 3.414B |
| July 21, 2026 | 3.495B |
| July 20, 2026 | 3.436B |
| Date | Value |
|---|---|
| July 17, 2026 | 3.524B |
| July 16, 2026 | 3.529B |
| July 15, 2026 | 3.579B |
| July 14, 2026 | 3.505B |
| July 13, 2026 | 3.507B |
| July 10, 2026 | 3.631B |
| July 09, 2026 | 3.663B |
| July 08, 2026 | 3.593B |
| July 07, 2026 | 3.627B |
| July 06, 2026 | 3.553B |
| July 02, 2026 | 3.588B |
| July 01, 2026 | 3.455B |
| June 30, 2026 | 3.472B |
| June 29, 2026 | 3.511B |
| June 26, 2026 | 3.531B |
| June 25, 2026 | 3.258B |
| June 24, 2026 | 3.196B |
| June 23, 2026 | 3.066B |
| June 22, 2026 | 2.979B |
| June 18, 2026 | 2.898B |
| June 17, 2026 | 2.895B |
| June 16, 2026 | 2.782B |
| June 15, 2026 | 2.837B |
| June 12, 2026 | 2.808B |
| June 11, 2026 | 2.859B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Incyte Corp. | 21.19B |
| Agios Pharmaceuticals, Inc. | 1.386B |
| Biogen, Inc. | 39.09B |
| Insmed, Inc. | 27.04B |
| Vertex Pharmaceuticals, Inc. | 132.96B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 31.50M |
| Revenue (Quarterly) | 307.96M |
| Total Expenses (Quarterly) | 276.46M |
| EPS Diluted (Quarterly) | 0.1822 |
| Gross Profit Margin (Quarterly) | 90.81% |
| Profit Margin (Quarterly) | 10.23% |
| Earnings Yield | 7.49% |
| Operating Earnings Yield | 1.70% |
| Normalized Earnings Yield | 7.494 |